L. Lomax

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.

M. Ranson, A. Arance, P. Lorigan, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized P hase I I S tudy o f T emozolomide G iven E very 8 Hours o r D aily W ith E ither I nterferon A lfa-2b o r T halidomide in M etastatic M alignant M elanoma

M. Ranson, A. Arance, P. Lorigan, 2003 .

Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer response and survival results

A. Arance, N. Thatcher, L. Ashcroft, 2002, British Journal of Cancer.

Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: a randomized phase II trial in small-cell lung cancer patients.

P. Woll, N. Thatcher, R. Pettengell, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.

P. Woll, N. Thatcher, V. Cour-Chabernaud, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised phase II study of standard versus dose-intensive ICE chemotherapy with reinfusion of haemopoietic progenitors in whole blood in small cell lung cancer (SCLC).

P. Woll, N. Thatcher, S. Lee, 1996 .

Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer.

P. Barber, P. Hopwood, R. Swindell, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

P-574 Randomised phase 3 trial of autologous blood progenitor cell and filgrastim supported dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) — a different toxicity profile

P. Lorigan, P. Woll, N. Thatcher, 2003 .